A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Trial Profile

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Tisagenlecleucel-T (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms JULIET
  • Sponsors Novartis
  • Most Recent Events

    • 25 Jun 2017 Interim analysis results presented at the 22nd Congress of the European Haematology Association
    • 24 Jun 2017 According to a European Hematology Association media release, interim results from this trial presented at the European Hematology Association Annual Congress.
    • 23 Jun 2017 According to a Novartis media release, data will be presented at the European Hematology Association (EHA) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top